Original language | English |
---|---|
Pages (from-to) | 1045-1083 |
Number of pages | 39 |
Journal | Journal of Infection and Chemotherapy |
Volume | 28 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2022 Aug |
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. / Kunishima, Hiroyuki; Ohge, Hiroki; Suzuki, Hiromichi et al.
In: Journal of Infection and Chemotherapy, Vol. 28, No. 8, 08.2022, p. 1045-1083.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection
AU - Kunishima, Hiroyuki
AU - Ohge, Hiroki
AU - Suzuki, Hiromichi
AU - Nakamura, Atsushi
AU - Matsumoto, Kazuaki
AU - Mikamo, Hiroshige
AU - Mori, Nobuaki
AU - Morinaga, Yoshitomo
AU - Yanagihara, Katsunori
AU - Yamagishi, Yuka
AU - Yoshizawa, Sadako
N1 - Funding Information: Hiroshige Mikamo received scholarship funds from Asahi Kasei Pharma Corp., Astellas Pharma Inc., MSD K.K., Eneforest Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Pfizer Japan Inc., FUJIFILM Pharma Co., Ltd., Hologic Japan Inc., Miyarisan Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Formulation of the present guidelines was entirely funded by the Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Funding Information: Yoshitomo Morinaga received scholarship funds from SRL, Inc., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Toyama Chemical Co., Ltd., Astellas Pharma Inc., Mitsui Chemicals, Inc., and MSD K.K. Funding Information: Katsunori Yanagihara received scholarship funds from SRL, Inc., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Toyama Chemical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsui Chemicals, Inc., MSD K.K., Shionogi & Co., Ltd., Nippon Becton Dickinson Co., Ltd., Hitachi High Technologies Co., Ltd., and Beckman Coulter K.K. Funding Information: Yuka Yamagishi received scholarship funds from MSD K.K., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Eneforest Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Toyama Chemical Co., Ltd., Pfizer Japan Inc., FUJIFILM Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Hiroki Ohge received scholarship funds from Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd.
PY - 2022/8
Y1 - 2022/8
UR - http://www.scopus.com/inward/record.url?scp=85130915864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130915864&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2021.12.011
DO - 10.1016/j.jiac.2021.12.011
M3 - Article
C2 - 35618618
AN - SCOPUS:85130915864
VL - 28
SP - 1045
EP - 1083
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 8
ER -